{"nctId":"NCT03495102","briefTitle":"A Study of the Efficacy and Safety of Dulaglutide (LY2189265) in Participants With Type 2 Diabetes","startDateStruct":{"date":"2018-04-05","type":"ACTUAL"},"conditions":["Diabetes Mellitus, Type 2"],"count":1842,"armGroups":[{"label":"Dulaglutide 1.5 mg","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Dulaglutide"]},{"label":"Dulaglutide 3 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Dulaglutide"]},{"label":"Dulaglutide 4.5 mg","type":"EXPERIMENTAL","interventionNames":["Drug: Dulaglutide"]}],"interventions":[{"name":"Dulaglutide","otherNames":["LY2189265"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Have type 2 diabetes mellitus (T2DM) for at least 6 months\n* Have been treated with stable metformin dose for at least 3 months\n* Have HbA1c ≥7.5% and ≤11.0% at study entry\n* Have body mass index (BMI) ≥25 kilograms per meter squared (kg/m\\^2)\n\nExclusion Criteria:\n\n* Have type 1 diabetes mellitus\n* Have used any glucagon-like peptide-1 receptor agonist (GLP-1 RA) or insulin, not including prior short term insulin use (≤14 days)\n* Have been taking any other medicine for diabetes (other than metformin) during the last 3 months\n* Have used in the last 3 months (or plan to use) prescription weight loss medications\n* Have disorders associated with slowed emptying of the stomach contents, or have had any stomach surgeries for the purpose of weight loss\n* Current participation in or intent to begin during the study an organized diet and/or exercise weight reduction program (other than the lifestyle and dietary measures for diabetes)\n* Have acute or chronic hepatitis, signs and symptoms of any other liver disease other than nonalcoholic fatty liver disease (NAFLD), or alanine transaminase (ALT) level \\>2.5 times the upper limit of the reference range, as determined by the central laboratory at study entry; participants with NAFLD are eligible for participation in this trial\n* Had chronic or acute pancreatitis any time prior to study entry\n* Have had a heart attack or stroke in the past 2 months, or have heart failure that significantly limits their physical activity\n* Estimated glomerular filtration rate (eGFR) \\<30 milliliters/minute/1.73m\\^2 (or lower than the country-specific threshold for discontinuing metformin therapy per local label), calculated by the Chronic Kidney Disease-Epidemiology (CKD-EPI) equation, as determined by the central laboratory at study entry and confirmed at lead-in\n* Have a personal or family history of medullary thyroid carcinoma or personal history of multiple endocrine neoplasia syndrome type 2\n* Have proliferative retinopathy or maculopathy requiring acute treatment according to the opinion of the investigator","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in Hemoglobin A1c (HbA1c) From Baseline","description":"HbA1c is measured to identify average plasma glucose concentration over prolonged periods of time. The Least Squares (LS) mean was estimated from a mixed-effects model with repeated measures (MMRM) that included the independent variables:Baseline + Pooled Country + Treatment + Time + Treatment\\*Time (Type III sum of squares).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.53","spread":"0.04"},{"groupId":"OG001","value":"-1.71","spread":"0.04"},{"groupId":"OG002","value":"-1.87","spread":"0.04"}]}]}]},{"type":"SECONDARY","title":"Change in Body Weight From Baseline","description":"Least Squares (LS) mean was determined by mixed-model repeated measures (MMRM) model with independent variables: Baseline + Baseline HbA1c group + Pooled Country + Treatment + Time + Treatment\\*Time (Type III sum of squares).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.1","spread":"0.19"},{"groupId":"OG001","value":"-4.0","spread":"0.19"},{"groupId":"OG002","value":"-4.7","spread":"0.19"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants Achieving HbA1c Target <7.0%","description":"Percentage of participants achieving HbA1c target \\<7.0%.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"56.98","spread":null},{"groupId":"OG001","value":"64.68","spread":null},{"groupId":"OG002","value":"71.48","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Fasting Serum Glucose (FSG) From Baseline","description":"Least Squares (LS) mean was determined by mixed-model repeated measures (MMRM) model with covariates: Baseline + Baseline HbA1c group + Pooled Country + Treatment + Time + Treatment\\*Time (Type III sum of squares).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-44.2","spread":"1.50"},{"groupId":"OG001","value":"-47.9","spread":"1.50"},{"groupId":"OG002","value":"-52.3","spread":"1.50"}]}]}]},{"type":"SECONDARY","title":"Rate of Documented Symptomatic Hypoglycemic Episodes","description":"Hypoglycemia was defined as blood glucose \\< 54 mg/dL, excluding post-rescue records. Estimate is based on Group Mean from negative binomial model. The negative binomial model for post-baseline comparisons between treatments and control group: Number of episodes = Pooled Country + HbA1c at Baseline (%) + Treatment, with log (exposure in days/365.25) as an offset variable.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.02","spread":"0.01"},{"groupId":"OG001","value":"0.00","spread":"0.00"},{"groupId":"OG002","value":"0.02","spread":"0.01"}]}]}]},{"type":"SECONDARY","title":"Pharmacokinetic (PK): Steady-state Maximum Concentration(Cmax,ss)","description":"Pharmacokinetic (PK): Steady-state Maximum Concentration(Cmax,ss).","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"79.6","spread":null},{"groupId":"OG001","value":"159","spread":null},{"groupId":"OG002","value":"238","spread":null}]}]}]},{"type":"SECONDARY","title":"Pharmacokinetic (PK): Area Under the Curve AUC (0-168)ss at Steady State","description":"Pharmacokinetic (PK): Area Under the Curve AUC (0-168)ss at Steady State.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11200","spread":null},{"groupId":"OG001","value":"22300","spread":null},{"groupId":"OG002","value":"33400","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":53,"n":612},"commonTop":["Nausea","Diarrhoea","Vomiting","Nasopharyngitis","Dyspepsia"]}}}